|
1
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A National Cancer Data Base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995 [see comments].
Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kitamura Y, Shimizu K, Nagahama M, Sugino
K, Ozaki O, Mimura T, Ito K, Ito K and Tanaka S: Immediate causes
of death in thyroid carcinoma: Clinicopathological analysis of 161
fatal cases. J Clin Endocrinol Metab. 84:4043–4049. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: ThyroidAmerican Joint Committee
on Cancer: AJCC Cancer Staging Manual. 6th. Springer-Verlag; New
York, NY: pp. 772002
|
|
4
|
Miccoli P, Materazzi G, Antonelli A,
Panicucci E, Frustaci G and Berti P: New trends in the treatment of
undifferentiated carcinomas of the thyroid. Langenbecks Arch Surg.
392:397–404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kebebew E: Anaplastic thyroid cancer:
Rare, fatal, and neglected. Surgery. 152:1088–1089. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Crevoisier R, Baudin E, Bachelot A,
Leboulleux S, Travagli JP, Caillou B and Schlumberger M: Combined
treatment of anaplastic thyroid carcinoma with surgery,
chemotherapy, and hyperfractionated accelerated external
radiotherapy. Int J Radiat Oncol Biol Phys. 60:1137–1143. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Smallridge RC, Ain KB, Asa SL, Bible KC,
Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal
MS, et al: American Thyroid Association Anaplastic Thyroid Cancer
Guidelines Taskforce: American Thyroid Association guidelines for
management of patients with anaplastic thyroid cancer. Thyroid.
22:1104–1139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Antonelli A, Fallahi P, Ferrari SM,
Ruffilli I, Santini F, Minuto M, Galleri D and Miccoli P: New
targeted therapies for thyroid cancer. Curr Genomics. 12:626–631.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jasim S, Ozsari L and Habra MA:
Multikinase inhibitors use in differentiated thyroid carcinoma.
Biologics. 8:281–291. 2014.PubMed/NCBI
|
|
10
|
Johanson V, Ahlman H, Bernhardt P, Jansson
S, Kölby L, Persson F, Stenman G, Swärd C, Wängberg B, Stridsberg
M, et al: A transplantable human medullary thyroid carcinoma as a
model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat
Cancer. 14:433–444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wells SA Jr, Robinson BG, Gagel RF, Dralle
H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR,
et al: Vandetanib in patients with locally advanced or metastatic
medullary thyroid cancer: A randomized, double-blind phase III
trial. J Clin Oncol. 30:134–141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cooper MR, Yi SY, Alghamdi W, Shaheen DJ
and Steinberg M: Vandetanib for the treatment of medullary thyroid
carcinoma. Ann Pharmacother. 48:387–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leboulleux S, Bastholt L, Krause T, de la
Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F,
Leenhardt L, Soufflet C, et al: Vandetanib in locally advanced or
metastatic differentiated thyroid cancer: A randomised,
double-blind, phase 2 trial. Lancet Oncol. 13:897–905. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
AstraZeneca, . Evaluation of Efficacy,
Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
(VERIFY) [ClinicalTrials.gov Identifier: NCT01876784].
2016.Available from. https://www.clinicaltrials.gov/ct2/show/NCT01876784Last
Update Posted: September 6, 2017.
|
|
15
|
Antonelli A, Ferrari SM, Fallahi P, Berti
P, Materazzi G, Barani L, Marchetti I, Ferrannini E and Miccoli P:
Primary cell cultures from anaplastic thyroid cancer obtained by
fine-needle aspiration used for chemosensitivity tests. Clin
Endocrinol (Oxf). 69:148–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Antonelli A, Ferrari SM, Fallahi P, Berti
P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P and
Ferrannini E: Evaluation of the sensitivity to chemotherapeutics or
thiazolidinediones of primary anaplastic thyroid cancer cells
obtained by fine-needle aspiration. Eur J Endocrinol. 159:283–291.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Antonelli A, Ferrari SM, Fallahi P, Berti
P, Materazzi G, Minuto M, Giannini R, Marchetti I, Barani L, Basolo
F, et al: Thiazolidinediones and antiblastics in primary human
anaplastic thyroid cancer cells. Clin Endocrinol (Oxf). 70:946–953.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fiore L, Pollina LE, Fontanini G, Casalone
R, Berlingieri MT, Giannini R, Pacini F, Miccoli P, Toniolo A,
Fusco A, et al: Cytokine production by a new undifferentiated human
thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab.
82:4094–4100. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agretti P, De Marco G, De Servi M,
Marcocci C, Vitti P, Pinchera A and Tonacchera M: Evidence for
protein and mRNA TSHr expression in fibroblasts from patients with
thyroid-associated ophthalmopathy (TAO) after adipocytic
differentiation. Eur J Endocrinol. 152:777–784. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Copland JA, Marlow LA, Williams SF, Grebe
SK, Gumz ML, Maples WJ, Silverman VE and Smallridge RC: Molecular
diagnosis of a BRAF papillary thyroid carcinoma with multiple
chromosome abnormalities and rare adrenal and hypothalamic
metastases. Thyroid. 16:1293–1302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Christensen L, Blichert-Toft M, Brandt M,
Lange M, Sneppen SB, Ravnsbaek J, Mollerup CL, Strange L, Jensen F,
Kirkegaard J, et al: Thyroperoxidase (TPO) immunostaining of the
solitary cold thyroid nodule. Clin Endocrinol (Oxf). 53:161–169.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Antonelli A, Ferrari SM, Fallahi P,
Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P,
Benvenga S, et al: Dysregulation of secretion of CXC
alpha-chemokine CXCL10 in papillary thyroid cancer: Modulation by
peroxisome proliferator-activated receptor-gamma agonists. Endocr
Relat Cancer. 16:1299–1311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Antonelli A, Bocci G, La Motta C, Ferrari
SM, Fallahi P, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti
A, et al: Novel pyrazolopyrimidine derivatives as tyrosine kinase
inhibitors with antitumoral activity in vitro and in vivo in
papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab.
96:E288–E296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Antonelli A, Bocci G, La Motta C, Ferrari
SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A,
Sartini S, Minuto M, et al: CLM94, a novel cyclic amide with
anti-VEGFR-2 and antiangiogenic properties, is active against
primary anaplastic thyroid cancer in vitro and in vivo. J Clin
Endocrinol Metab. 97:E528–E536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bocci G, Fioravanti A, La Motta C, Orlandi
P, Canu B, Di Desidero T, Mugnaini L, Sartini S, Cosconati S, Frati
R, et al: Antiproliferative and proapoptotic activity of CLM3, a
novel multiple tyrosine kinase inhibitor, alone and in combination
with SN-38 on endothelial and cancer cells. Biochem Pharmacol.
81:1309–1316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Antonelli A, Fallahi P, Ulisse S, Ferrari
SM, Minuto M, Saraceno G, Santini F, Mazzi V, D'Armiento M and
Miccoli P: New targeted therapies for anaplastic thyroid cancer.
Anticancer Agents Med Chem. 12:87–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gule MK, Chen Y, Sano D, Frederick MJ,
Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, et al:
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth
of anaplastic thyroid cancer in an orthotopic murine model. Clin
Cancer Res. 17:2281–2291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
La Motta C, Mugnaini L, Sartini S, Da
Settimo F, Bocci G, Fioravanti A, Del Tacca M and Martini C: 2007
Derivati a nucleo pirazolo (3,4-d) pirimidinico quali inibitori di
proteina tirosina chinasi. RM2007A000480 del 14/9/2007.
|
|
29
|
Liu Z, Hou P, Ji M, Guan H, Studeman K,
Jensen K, Vasko V, El-Naggar AK and Xing M: Highly prevalent
genetic alterations in receptor tyrosine kinases and
phosphatidylinositol 3-kinase/akt and mitogen-activated protein
kinase pathways in anaplastic and follicular thyroid cancers. J
Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shinohara M, Chung YJ, Saji M and Ringel
MD: AKT in thyroid tumorigenesis and progression. Endocrinology.
148:942–947. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Santarpia L, El-Naggar AK, Cote GJ, Myers
JN and Sherman SI: Phosphatidylinositol 3-kinase/akt and
ras/raf-mitogen-activated protein kinase pathway mutations in
anaplastic thyroid cancer. J Clin Endocrinol Metab. 93:278–284.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Di Desidero T, Fioravanti A, Orlandi P,
Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F,
et al: Antiproliferative and proapoptotic activity of sunitinib on
endothelial and anaplastic thyroid cancer cells via inhibition of
Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
J Clin Endocrinol Metab. 98:E1465–E1473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Antonelli A, Bocci G, Fallahi P, La Motta
C, Ferrari SM, Mancusi C, Fioravanti A, Di Desidero T, Sartini S,
Corti A, et al: CLM3, a multitarget tyrosine kinase inhibitor with
antiangiogenic properties, is active against primary anaplastic
thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab.
99:E572–E581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Klein EA and Assoian RK: Transcriptional
regulation of the cyclin D1 gene at a glance. J Cell Sci.
121:3853–3857. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss
N, Clifton-Bligh R, Staaf J, Borg A, Delbridge L, Robinson BG, et
al: Array-CGH identifies cyclin D1 and UBCH10 amplicons in
anaplastic thyroid carcinoma. Endocr Relat Cancer. 15:801–815.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wiseman SM, Masoudi H, Niblock P, Turbin
D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D and Gilks B:
Anaplastic thyroid carcinoma: Expression profile of targets for
therapy offers new insights for disease treatment. Ann Surg Oncol.
14:719–729. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sarkar S, Mazumdar A, Dash R, Sarkar D,
Fisher PB and Mandal M: ZD6474, a dual tyrosine kinase inhibitor of
EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces
apoptosis in breast cancer cells. Cancer Biol Ther. 9:592–603.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ye L, Santarpia L and Gagel RF: The
evolving field of tyrosine kinase inhibitors in the treatment of
endocrine tumors. Endocr Rev. 31:578–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Blumenthal RD and Goldenberg DM: Methods
and goals for the use of in vitro and in vivo chemosensitivity
testing. Mol Biotechnol. 35:185–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Antonelli A, Ferri C, Ferrari SM,
Sebastiani M, Colaci M, Ruffilli I and Fallahi P: New targeted
molecular therapies for dedifferentiated thyroid cancer. J Oncol.
2010:9216822010. View Article : Google Scholar : PubMed/NCBI
|
